NEW YORK (GenomeWeb) — Phosphorus announced today that it has received a clinical laboratory permit, as well as approvals for two of its next-generation sequencing-based diagnostics, from the New York State Department of Health (NYSDOH).
The lab-developed tests are designed to detect genetic variations — including SNPs, insertion-deletions, copy number variations, and variations in segmental duplications — in blood and saliva samples. Phosphorus said that one test screens for hereditary cancers and the other for arrhythmias, cardiomyopathies, and lipidemias.
With the NYSDOH molecular genetic testing permit, the New York City-based company will be able to offer the tests in New York state as well as throughout the US.